Abstract | PURPOSE: EXPERIMENTAL DESIGN: This phase I, open-label, dose-escalation study assessed the tolerability and toxicity profile of > or =2 doses of mapatumumab administered i.v. in patients with advanced solid tumors. Patients received mapatumumab every 28 days until progression or dose-limiting toxicity. RESULTS: There were escalation levels from 0.01 to 20.0 mg/kg. Forty-one patients, 27 female, with a median age of 55 years (range, 23-81) were entered into the study and received 143 courses. The most common diagnoses were colorectal (10 patients) and ovarian cancer (9 patients). Patients received a median of two cycles (range, 1-33). Mapatumumab was well tolerated. Adverse events considered at least possibly related to mapatumumab that occurred most frequently included fatigue (36.2%), hypotension (34.1%), nausea (29.3%), and pyrexia (12.2%). The majority of adverse events were grade 1 or 2. The maximum tolerated dose was not reached. Linear pharmacokinetics was observed for doses up to 0.3 mg/kg and for the 20 mg/kg level, whereas exposure at 3 and 10 mg/kg increased less than proportionally. No objective responses were observed, but 12 patients had stable disease for 1.9 to 29.4 months. CONCLUSIONS:
Mapatumumab is well tolerated and further evaluation of this TRAIL-R1 targeting agent is warranted.
|
Authors | Sébastien J Hotte, Hal W Hirte, Eric X Chen, Lillian L Siu, Lyly H Le, Alfred Corey, Anne Iacobucci, Martha MacLean, Larry Lo, Norma Lynn Fox, Amit M Oza |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 14
Issue 11
Pg. 3450-5
(Jun 01 2008)
ISSN: 1078-0432 [Print] United States |
PMID | 18519776
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- mapatumumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, adverse effects, pharmacokinetics)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
(administration & dosage, adverse effects, pharmacokinetics)
- Drug Administration Schedule
- Female
- Half-Life
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
|